Tiapride versus glafenine: a double-blind comparative study in the management of acute rheumatic pain.
A double-blind study was carried out in 42 patients suffering from acute rheumatic pain to compare the analgesic effectiveness and tolerance of tiapride with that of glafenine, a widely used analgesic in Europe. Patients were allocated at random to receive either 100 mg tiapride or 200 mg glafenine 3-times daily over a period of 14 days. Pain intensity was rated daily by the patients using a visual analogue scale and an overall assessment of response to treatment was made by both patients and physician at the end of the study. The results showed that, whilst both treatments resulted in a marked reduction in mean pain scores, pain disappeared completely in 16 (76%) of the 21 patients treated with tiapride compared with 9 (43%) of the 21 receiving glafenine. There was also a significant difference in favour of tiapride in the physician's overall assessment of response which was considered as excellent in 71% of the patients on tiapride compared with 31% receiving glafenine. Both treatments were well tolerated and few side-effects were reported. Drowsiness occurred in 6 patients on tiapride but this was only mild in 5 and moderate in the other patient.
D000328:Adult; D000368:Aged; D001549:Benzamides / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005897:Glafenine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy*; D012216:Rheumatic Diseases; D012894:Sleep Stages / Q000187:drug effects; D013976:Tiapamil Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D062367:ortho-Aminobenzoates / Q000627:therapeutic use*
D001549:Benzamides; D062367:ortho-Aminobenzoates; D005897:Glafenine; D013976:Tiapamil Hydrochloride